Deals: Page 4
-
Courtesy of AbbVie
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is that it could create "another formidable competitor” to drug delivery specialist Denali Therapeutics.
By Jacob Bell • Updated Oct. 28, 2024 -
Nemes Laszlo via Getty Images
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact
The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell will also end development of two current pipeline programs.
By Ben Fidler • Oct. 24, 2024 -
Courtesy of Sanofi
Sanofi moves ahead with CD&R deal for stake in consumer business
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
By Delilah Alvarado • Oct. 21, 2024 -
Courtesy of Viatris
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.
By Kristin Jensen • Oct. 17, 2024 -
Elizabeth Regan/BioPharma Dive
Lundbeck to buy brain drug developer Longboard for $2.6B
The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.
By Jacob Bell • Oct. 14, 2024 -
Courtesy of Sanofi
Sanofi may have found a buyer for its consumer health business
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
By Jacob Bell • Oct. 11, 2024 -
Courtesy of Sanofi
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
By Jacob Bell • Oct. 4, 2024 -
Courtesy of Roche
Roche turns to a startup in search for new breast cancer drugs
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
By Jonathan Gardner • Sept. 30, 2024 -
Permission granted by Roivant Sciences
Roivant dermatology subsidiary to be acquired by Organon
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
By Kristin Jensen • Sept. 18, 2024 -
Mario Tama via Getty Images
Judge orders J&J to pay Auris investors more than $1B for merger violations
J&J did not provide Auris Health with resources to achieve regulatory milestones after acquiring the robotics company in 2019, the judge found.
By Ricky Zipp • Sept. 6, 2024 -
Dr_Microbe via Getty Images
Startup Halda raises $126M to advance new type of targeted cancer therapy
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
By Jonathan Gardner • Updated Aug. 13, 2024 -
Courtesy of Merck & Co.
Immune resetMerck bets $700M on an antibody drug’s potential in immune diseases
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
By Ben Fidler • Aug. 9, 2024 -
Newbird via Getty Images
Emerging biotechWith pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Recent data from J.P. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks.
By Gwendolyn Wu • Aug. 9, 2024 -
Permission granted by Recursion Pharmaceuticals
Recursion to absorb Exscientia in ‘techbio’ deal
The two AI drug discovery firms, which have each lost most of their value since going public, believe their complementary skills can better speed the development of new medicines.
By Kristin Jensen • Aug. 8, 2024 -
Courtesy of Boehringer Ingelheim
Boehringer adds to cancer drug pipeline with deal for startup Nerio
The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.
By Ned Pagliarulo • July 29, 2024 -
Brian Tucker/BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 22, 2024 -
Permission granted by Boehringer Ingelheim
Boehringer cuts price of Humira biosimilar in bid to build use
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
By Jonathan Gardner • July 18, 2024 -
Jolygon via Getty Images
Cardurion raises another $260M to fuel heart drug pipeline
The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines.
By Jonathan Gardner • July 16, 2024 -
Permission granted by Sionna Therapeutics
Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex
The startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.
By Ben Fidler • July 16, 2024 -
jetcityimage via Getty Images
Lilly to buy Morphic in $3B bet on inflammation drug
The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.
By Jacob Bell • July 8, 2024 -
Scott Olson via Getty Images
Eli Lilly inks another radiopharma deal, gaining option to buy startup
Under an arrangement with Radionetics, Lilly will have rights to acquire the San Diego biotechnology company for $1 billion.
By Delilah Alvarado • July 1, 2024 -
Courtesy of Eisai
Eisai and Bristol Myers cancel cancer ADC deal
The Japan-based drugmaker said its U.S. partner’s “portfolio prioritization efforts” led to the termination. It will refund part of an upfront payment.
By Jonathan Gardner • July 1, 2024 -
Courtesy of AbbVie
AbbVie expands its IBD prospects with $250M Celsius deal
The pharma’s acquisition of Celsius is the latest in a string of deals by major drugmakers hunting anti-inflammatory medicines.
By Gwendolyn Wu • June 27, 2024 -
Courtesy of AbbVie
AbbVie joins in latest gastrointestinal drug chase
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
By Jonathan Gardner • June 14, 2024 -
Courtesy of Seres Therapeutics
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
Seres did not disclose financial details for the deal, but said it would help extend the company's cash runway by one year.
By Kristin Jensen • June 6, 2024
Previous
